<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, April 5, 2018 (HealthDay News) — A composite implant, termed the California Project to Cure Blindness-Retinal Pigment Epithelium 1 (CPCB-RPE1), which consists of a polarized monolayer of human embryonic stem cell-derived RPE (hESC-RPE) on an ultrathin parylene substrate, may improve visual function in some patients with non-neovascular age-related macular degeneration (NNAMD), according to a study published online April 4 in Science Translational Medicine<\/i>.<\/p>\n
Amir H. Kashani, M.D., Ph.D., from the University of Southern California in Los Angeles, and colleagues conducted an interventional U.S. Food and Drug Administration-cleared phase 1\/2a study to assess the safety and efficacy of a in patients with advanced NNAMD.<\/p>\n
In an interim analysis of the phase 1 cohort comprising five subjects, four of the subjects successfully received the composite implant. The researchers identified changes consistent with hESC-RPE in all implanted subjects on optical coherence tomography imaging, as well as host photoreceptor integration. There was no progression to vision loss in any of the implanted eyes; one eye improved by 17 letters, and two demonstrated improved fixation.<\/p>\n
“The concurrent structural and functional findings suggest that CPCB-RPE1 may improve visual function, at least in the short term, in some patients with severe vision loss from advanced NNAMD,” the authors write.<\/p>\n
Several authors disclosed financial ties to Regenerative Patch Technologies and\/or are named as inventors on patents associated with the technology described in this publication; Regenerative Patch Technologies holds an exclusive license to these patents.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n